KCNC1 and cardiovascular disorder: Given that repaglinide is already a mature drug that can improve type 2 diabetes and cardiovascular events, further investigation of the effect of repaglinide on KV4 currents in different tissue will be a potential way to improve KChIPs-related neurological and cardiovascular diseases.